HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,100.00
-15.00 (-0.48%)
Aug 28, 2025, 3:30 PM KST
-0.48%
Market Cap260.33B
Revenue (ttm)61.23B
Net Income (ttm)-5.07B
Shares Out83.98M
EPS (ttm)-60.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume349,493
Average Volume510,361
Open3,100.00
Previous Close3,100.00
Day's Range3,040.00 - 3,140.00
52-Week Range2,885.00 - 13,619.03
Beta-0.86
RSI20.73
Earnings DateAug 14, 2025

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 49
Stock Exchange KOSDAQ
Ticker Symbol 115450
Full Company Profile

Financial Performance

In 2024, HLB Therapeutics's revenue was 54.93 billion, an increase of 4.45% compared to the previous year's 52.59 billion. Losses were -22.79 billion, 890.1% more than in 2023.

Financial Statements

News

There is no news available yet.